Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCB | P10092 | 3/20 | 0.47 |
| ▸ | CALCRL | Q16602 | 16/20 | 0.46 |
| ▸ | ADM2 | Q7Z4H4 | 3/20 | 0.44 |
| ▸ | RAMP1 | O60894 | 2/20 | 0.44 |
| ▸ | CALCA | P06881 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3050811 | 1.00 | CALCB (0.47) | CALCBCALCRLADM2RAMP1CALCA | |
| SCHEMBL3043260 | 1.00 | CALCB (0.47) | CALCBCALCRLADM2RAMP1CALCA | |
| SCHEMBL3168719 | 0.99 | CALCB (0.47) | CALCBCALCRLADM2RAMP1CALCA | |
| SCHEMBL3044880 | 0.91 | CALCRL (0.46) | CALCBCALCRLADM2 | |
| SCHEMBL3047139 | 0.90 | CALCRL (0.44) | CALCBCALCRLADM2RAMP1CALCA | |
| SCHEMBL550410 | 0.90 | CALCRL (0.46) | CALCBCALCRLADM2RAMP1CALCA | |
| SCHEMBL3039948 | 0.88 | CALCB (0.48) | CALCBCALCRLADM2RAMP1CALCA | |
| SCHEMBL550275 | 0.88 | CALCB (0.43) | CALCBCALCRLADM2 | |
| SCHEMBL3044651 | 0.87 | CALCRL (0.43) | CALCBCALCRLADM2 | |
| SCHEMBL549094 | 0.87 | CALCRL (0.42) | CALCBCALCRLADM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225227-B1 | 1',3'-Dihydrospiro[imidazolidin-4,2'-inden]-2,5-diones and 1,3-dihydrospiro[inden-2,3']-pyrroles as CGRP antagonists | BOEHRINGER INGELHEIM INT (DE) | 2015-08-26 | — | — | EP | disclosed |
| US-8110575-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-07 | — | — | US | disclosed |
| US-8110575-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-07 | — | — | US | disclosed |
| US-20110021500-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021500-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2251339-A2 | COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009065920-A2 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021500-A1 | NOVEL COMPOUNDS | CALCRL, CALCR, CALCA | CALCB 9/4885CALCRL 1/4885ADM2 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.